BioSpace News Archive

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended August 31, 2023, and provided a corporate update.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”) today provided an update on its Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) who have achieved complete remission following second-line salvage therapy (CR2 patients).

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2023 financial results on Monday, October 30, 2023, at 4:30 pm Eastern Time.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced preliminary unaudited financial results for the third quarter ended September 30, 2023 and business updates.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells.

Bexion Pharmaceuticals, Inc. announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum.

Ultragenyx Pharmaceutical Inc. reported the grant of 80,366 restricted stock units of the company’s common stock and the grant of non-qualified stock options to purchase an aggregate of 140,469 shares of common stock of the company to Howard Horn, its newly appointed Chief Financial Officer and Executive Vice President, Corporate Strategy.

Ascentage Pharma announced that the Center for Drug Evaluation of China NMPA has approved a global pivotal registrational Phase III study designed to evaluate a key drug candidate in Ascentage Pharma’s pipeline, Bcl-2 inhibitor APG-2575, in combination with the Bruton’s tyrosine kinase inhibitor acalabrutinib.

Anbio Biotechnology (“Anbio”), a leading provider of innovative diagnostic solutions, successfully showcased its debut at AACC Middle East 2023 held in Dubai from October 7-8, 2023.

Global market leader in molded glass packaging solutions for the pharmaceutical industry, SGD Pharma announces the latest expansion of its Sterinity range of Ready-To-Use (RTU) Type I molded glass vials.